SAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint

SAB Biotherapeutics (SABS) announced positive, confirmatory data from a Phase 1 trial of SAB-142 in a single- and multiple-ascending dose among healthy volunteers, including a re-dosed cohort, and T1D patients. The study met its primary objectives to establish a safety profile and characterize pharmacodynamic activity enabling SAB-142 to advance to Phase 2b clinical development in the SAFety and Efficacy of human anti-thymocyte immunoGlobUlin SAB-142 ARresting progression of type 1 Diabetes clinical trial, now underway. Based on these data, SAB BIO has advanced SAB-142 into a registrational Phase 2b trial SAFEGUARD to evaluate SAB-142 in adult and pediatric patients with new-onset, stage 3 T1D. The SAFEGUARD trial is enrolling at multiple sites around the world, and the Company is on track to dose the first patient by the end of the year.